Statistics from Altmetric.com
The publication of the EULAR/ACR classification criteria for ‘idiopathic inflammatory myopathy’ group of disease would be considered a landmark work in this field.1 The tremendous efforts of a large number of dedicated workers in the field of myositis from around the world coming together to produce this seminal document deserve high praise. The hope is that it will aid the drug trials on homogeneous subsets of this group of diseases yielding meaningful results. However, there is some concern for ‘an outsider’, a general rheumatologist like me, for not putting more emphasis on myositis-specific antibodies (MSAs). Most of the authors of this document …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.